No validated predictive biomarkers for antiangiogenic treatment of metastatic renal cell carcinoma (mRCC) exist. Tumor vascular endothelial growth factor A (VEGF-A) level may be useful. We determined tumor uptake of 89 Zr-bevacizumab, a VEGF-A-binding PET tracer, in mRCC patients before and during antiangiogenic treatment in a pilot study. Methods: Patients underwent 89 Zrbevacizumab PET scans at baseline and 2 and 6 wk after initiating either bevacizumab (10 mg/kg every 2 wk) with interferon-α (3-9 million IU 3 times/wk) (n 5 11) or sunitinib (50 mg daily, 4 of every 6 wk) (n 5 11). Standardized uptake values were compared with plasma VEGF-A and time to disease progression. Results: 89 Zrbevacizumab PET scans visualized 125 evaluable tumor lesions in 22 patients, with a median SUV max (maximum standardized uptake value) of 6.9 (range, 2.3-46.9). Bevacizumab/interferon-α induced a mean change in tumor SUV max of −47.0% (range, −84.7 to 120.0%; P , 0.0001) at 2 wk and an additional −9.7% (range, −44.8 to 138.9%; P 5 0.015) at 6 wk. In the sunitinib group, the mean change in tumor SUV max was −14.3% at 2 wk (range, −80.4 to 1269.9; P 5 0.006), but at 6 wk the mean change in tumor SUV max was 172.6% (range, −46.4 to 1236%; P , 0.0001) above baseline. SUV max was not related to plasma VEGF-A at all scan moments. A baseline mean tumor SUV max greater than 10.0 in the 3 most intense lesions corresponded with longer time to disease progression (89.7 vs. 23.0 wk; hazard ratio, 0.22; 95% confidence interval, 0.05-1.00). Conclusion: Tumor uptake of 89 Zr-bevacizumab is high in mRCC, with remarkable interpatient and intrapatient heterogeneity. Bevacizumab/interferon-α strongly decreases tumor uptake whereas sunitinib results in a modest reduction with an overshoot after 2 drugfree weeks. High baseline tumor SUV max was associated with longer time to progression.
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Key Words: renal cell carcinoma; molecular imaging; positron emission tomography; bevacizumab; sunitinib Angi ogenesis inhibitors have single-agent activity and double median progression-free survival in patients with metastatic renal cell carcinoma (mRCC) (1-3). However, not all patients respond, and angiogenesis inhibitors are expensive and can have side effects. Furthermore, studies indicated potential tumor-promoting effects of tyrosine kinase inhibitors (4, 5) . Therefore, it is crucial to develop a predictive biomarker for selecting patients who will benefit from these treatments. Circulating vascular endothelial growth factor A (VEGF-A) levels do not predict benefit from antiangiogenic treatment (6) (7) (8) (9) (10) . VEGF-A, however, comprises different splice variants; small isoforms can diffuse freely whereas larger isoforms are primarily matrix-bound and have biologic activity in the tumor microenvironment (11) . Local VEGF-A concentration potentially reflects whether angiogenesis drives tumor progression and might predict sensitivity to antiangiogenic treatment. Therefore, we developed the PET tracer 89 Zr-bevacizumab, which enables noninvasive whole-body VEGF-A imaging and quantification (12) (13) (14) . Sunitinib and bevacizumab plus interferon-a (IFNa) are standard treatments for mRCC (1, 2) . Bevacizumab, a monoclonal antibody with a half-life of 620 d, binds VEGF-A, thus preventing the growth factor to activate its receptor. Sunitinib is a small molecule with a half-life of 62 d that blocks VEGF receptors and other tyrosine kinases intracellularly.
We conducted a pilot study in mRCC patients. Renal cell carcinoma (RCC) is characterized by Von Hippel-Lindau gene inactivation, resulting in high VEGF-A production and characteristic vascular tumors. The primary aim was to quantify 89 Zr-bevacizumab uptake in tumor lesions before treatment and changes in uptake during the early course of antiangiogenic therapy in mRCC patients. Furthermore, we wanted to explore whether 89 Zr-bevacizumab PET can early identify primary resistant disease (defined as progressive disease at first evaluation), whether tumor 89 Zr-bevacizumab uptake correlates with plasma VEGF-A, and the effect of 2 drug-free weeks after 4 wk of sunitinib on tumor 89 Zr-bevacizumab uptake.
MATERIALS AND METHODS

Patients
Adult mRCC patients with measurable disease were eligible. Exclusion criteria included uncontrolled hypertension, known untreated brain metastases, clinically significant cardiovascular disease, surgery, and tyrosine kinase inhibitor treatment up to 4 wk or bevacizumab up to 4 mo before trial entry. The study was approved by the institutional review board, and all subjects signed a written informed consent form. The trial is registered with ClinicalTrials.gov (NCT00831857).
Study Design and Treatment
The primary endpoint was change of tumor standardized uptake values (SUVs) at 2 and 6 wk after the start of treatment. Patients were randomized to bevacizumab (10 mg/kg intravenously every 14 d) with IFNa (3 million IU 3 times/wk), which was increased after 2 wk to 6 and then to 9 million IU when tolerated, or sunitinib (50 mg daily orally during 4 of every 6 wk). Treatment was continued until disease progression or unacceptable toxicity. After inclusion of 3 patients, the study was amended to a nonrandomized design because of slow accrual. Because no formal comparison of treatment groups was planned, randomization was not essential for conduct of the study. The secondary endpoint was progressive disease at 3 mo according to the Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST1.1).
Imaging Techniques
Patients underwent 89 Zr-bevacizumab PET imaging at baseline and 2 and 6 wk after the start of treatment. PET scanning was performed 4 d after intravenous administration of 37 MBq of 89 Zr-bevazicumab (5 mg protein dose). Two weeks was the minimum interval required to avoid interference of activity of the first 89 Zr-bevacizumab injection. Six weeks was chosen to explore a rebound phenomenon after 2 sunitinib-free weeks and to explore whether a scan after 3 therapeutic bevacizumab doses shows a further change. Conjugation and labeling were done as described earlier (13) . Patients were scanned from the upper thigh to the head in up to 8 consecutive bed positions, with a final reconstruction resolution of approximately 11 mm. Patients underwent routine CT imaging at baseline and every 3 mo thereafter. CT was performed with intravenous contrast with a maximal slice thickness of 5.0 mm (supplemental methods [available at http://jnm.snmjournals.org]). In the case of symptoms, bone scintigraphy and MR imaging were performed.
Imaging Data Analysis
Baseline PET scans were qualitatively assessed by a nuclear medicine physician and fused with the baseline CT scans to verify location and anatomic substrate of hot spots. All regions with high focal tracer uptake relative to normal-organ background were considered as lesions. Lesions were defined evaluable when identified as tumor lesion on routine imaging, greater than 10 voxels, delineable from normal-organ background, and not irradiated. Quantification was performed with AMIDE Medical Image Data Examiner software (version 0.9.1; Stanford University) (15) . Maximum and mean SUV (SUV max and SUV mean , respectively) were calculated for evaluable lesions and normal organs. All lesions on the baseline CT were measured for comparison with PET. Treatment response was assessed according to RECIST1.1 by a radiologist who was masked to patient characteristics and PET results.
Biomarker Analysis
Plasma VEGF-A was measured in samples drawn at days 23, 11, and 39 before tracer administration and stored at 280°C until analysis. Samples were analyzed with the immunologic multiparametric chip technique (7).
Statistical Assessments
We assumed that the difference in SUV between the baseline scan and the scan after 2 and 6 wk was 1.25 SDs or greater and that there was no correlation between the first and second scans and estimated that 11 patients were required in each treatment group to predict with 80% power (2-sided a 5 0.05) that there is a true difference. To compensate for an anticipated 15% early discontinuation, 26 patients were included. For comparison of paired and nonpaired data, Wilcoxon paired-rank and the Mann-Whitney tests were used. The association between SUV mean and SUV max was analyzed with Spearman rank correlation and between imaging results and time to disease progression (TTP) with the Kaplan-Meier method. Analyses were performed with SPSS (version 20; IBM).
RESULTS
Patients
Between February 2009 and July 2011, 26 patients were included. Two patients did not meet eligibility criteria because of recent bevacizumab treatment and were excluded from the analysis. One patient was not evaluable, and 1 patient withdrew consent. Therefore, 22 patients, 11 per treatment group, who underwent at least the baseline and 2-wk scans, were evaluable (Supplemental Fig. 1 ). One patient reported nausea, redness of the face, and cold extremities for 24 h after the third tracer injection but continued bevacizumab treatment without adverse events. Patient characteristics are shown in Table 1 .
Baseline 89 Zr-Bevacizumab PET Normal-Organ 89 Zr-Bevacizumab Uptake. An example of a baseline scan is shown in Figure 1 . SUV mean and SUV max of normal organs were strongly correlated (r 2 5 0.99, P , 0.0001, Supplemental Fig. 2A ). SUV max is less operator-dependent, so we used SUV max . Normal-organ uptake ( Fig. 2A) was consistent with a previous study (14) and with distribution of other antibody tracers (16, 17) .
Tumor 89 Zr-Bevacizumab Uptake. 89 Zr-bevacizumab PET visualized lesions in all patients. In total, 213 lesions were identified, of which 194 were in the field of view of the routine CT scan; 159 were also identified as tumor lesions on CT. The 35 lesions that were not detected on CT were located in the bone (n 5 12), lymph nodes (n 5 6), muscles (n 5 7), kidneys (n 5 4), and intraperitoneal (n 5 4) and retroperitoneal compartments (n 5 2). The 19 lesions outside the field of view of the CT scan were localized in the brain (n 5 5 in 3 patients), bone (n 5 4), lymph nodes (n 5 2), and muscles (n 5 8) ( Table 2) . Two patients with known brain metastases had radiotherapy before entry in the study. In the third patient, no MR imaging was performed. Sunitinib was started immediately because of rapidly progressive systemic disease without neurologic symptoms. On the CT scan, 562 lesions were identified, 145 in the bevacizumab/IFNa group and 417 in the sunitinib group, of which 231 were 10 mm or greater. The smallest lesion detected by 89 Zr-bevacizumab PET was 5.0 mm. The detection percentage increased with lesion size on CT ( Supplemental Fig. 3) ; 56.7% of lesions 10 mm or greater were visible with 89 Zr-bevacizumab PET. The 125 tumor lesions evaluable for quantification showed a strong correlation between SUV mean and SUV max (r 2 5 0.99, P , 0.0001, Supplemental Fig. 2B ). Therefore, only SUV max is reported. Median tumor SUV max was 6.9 (range, 2.3-46.9), varying from 3.8 (range, 2.7-15.4) for the patient with the lowest tumor uptake to 36.3 (range, 25.7-46.9) for the patient with the highest uptake (Fig. 2B) . Furthermore, tumor tracer uptake differed according to organ localization (Fig. 2C) . At baseline, median SUV max in 34 tumor lesions in the bevacizumab/ IFNa-treated patients was 8.1 (range, 2.3-46.9). At 2 wk, a mean change of 247.0% in tumor SUV max (range, 284.7 to 120.0%; P , 0.0001) was found, resulting in a median SUV max of 4.7 (range, 1.4-10.1; Fig. 3A ). This pattern was found in all patients (Supplemental Fig. 4A ). Tumor SUV max consistently decreased to 10 or less, even in lesions with high baseline uptake (Fig. 3B) . A third 89 Zr-bevacizumab PET scan, available in 9 patients, showed a further mean change of 29.7% (range, 244.8 to 138.9%; P 5 0.015) in tracer uptake in the 23 tumor lesions (Fig. 3A) . Figure 4A shows an example of serial scans. Small changes over time in normal-organ 89 Zr-bevacizumab uptake were detected (Supplemental Fig. 5A ). (Figs. 3C and 3D) . At the patient level, patterns were divergent (Supplemental Fig. 4B ). Mean change in tumor SUV max Fig. 3C ). Figure 4B shows an example of serial scans. Normal liver, kidney, and spleen uptake increased during sunitinib by 51.1%, 32.7%, and 25.0%, respectively, and returned to baseline after 2 drug-free weeks. In other normal organs, mean absolute changes did not exceed 1.0 SUV max (Supplemental Fig. 5B ).
Zr-Bevacizumab PET and Treatment Outcome
Eighteen patients were evaluable for tumor response at 3 mo (Table 3) . One patient with a sarcomatoid tumor component on bevacizumab/IFNa had progressive disease, 1 patient had a partial response, and 16 patients had stable disease. The patient with progressive disease had a mean baseline tumor SUV max of 6.4, which had decreased by 34% at 2 wk. Post hoc analysis showed that 16 patients (8 of both treatment groups) with a baseline tumor SUV max greater than 10.0 in the 3 most intense lesions had a longer TTP than 6 patients (3 of both treatment groups) with lower baseline tumor SUV max , with a median TTP of 89.7 versus 23.0 wk (hazard ratio, 0.22; 95% confidence interval, 0.05-1.00; P 5 0.050; Fig. 5 ). A cutoff of 10 was chosen because mean normal-organ SUV max was less than 10, and bevacizumab treatment reduced tumor uptake to less than 10. Change in tumor uptake and TTP did not correlate.
Plasma VEGF-A
Baseline plasma VEGF-A (n 5 20; median, 101.2 pg/mL; range, 15.4-445.1 pg/mL) did not correlate with tumor SUV max and mean tumor SUV max of all evaluable lesions and of the 3 most intense lesions. Plasma VEGF-A during bevacizumab treatment was unreliable and therefore not analyzed. In the sunitinib group, no relationship was found between plasma VEGF-A and tumor SUV max and mean tumor SUV max of all evaluable lesions and of the 3 most intense lesions at 2 and 6 wk. Also, changes in plasma VEGF-A did not correspond with changes in tumor SUV max parameters.
DISCUSSION
This pilot study in 22 mRCC patients demonstrates that 89 Zrbevacizumab PET visualizes tumor lesions, with major differences in tumor 89 Zr-bevacizumab uptake both between and within Including lesions outside field of view of CT scan: bone, n 5 4; lymph node, n 5 2; brain, n 5 5; muscle, n 5 8. patients. Antiangiogenic therapy alters tumor 89 Zr-bevacizumab uptake; a consistent large decrease occurs after the start of bevacizumab/IFNa and a heterogeneous response during sunitinib.
There was a striking heterogeneity in 89 Zr-bevacizumab tumor accumulation at baseline. In a subset of tumors, uptake did not exceed normal-organ background, reflected by visualization of only 56.7% of tumor lesions 10 mm or greater. Moreover, in evaluable lesions, large differences in SUV max were found, possibly indicating a difference in biology. Tracer accumulation is dependent on delivery by tumor vasculature and on the amount of target. Heterogeneity may therefore reflect differences in vascular characteristics and tumor VEGF-A production. We did not perform biopsies in the current study. However, a correlation between 111 In-bevacizumab tumor uptake and VEGF-A expression in melanoma lesions and between 89 Zr-bevacizumab tumor uptake and VEGF-A expression in primary breast cancer has been shown previously (13, 18) .
Interpatient tumor heterogeneity is increasingly recognized and used for personalized treatment. The heterogeneity of 89 Zr-bevacizumab tumor uptake between patients may offer a possibility to differentiate patient groups based on tumor biology. Intrapatient tumor heterogeneity has also drawn increasing attention (19, 20) . Exome sequencing of different parts of primary RCCs and associated metastatic sites demonstrated substantial mutational heterogeneity (19) . PET imaging has the potential to noninvasively visualize and quantify effects of mutations on expression of treatment targets across tumor lesions (21) . Whole-body insight in heterogeneity of tumor characteristics might guide choices of drug combinations or combinations of different treatment modalities in the future.
Formal comparison of treatment groups was not the aim of this pilot study. Nevertheless, the finding of increased 89 Zr-bevacizumab tumor accumulation at 2 wk in a subset of lesions during sunitinib suggests a difference in biologic effect of the 2 antiangiogenic regimens, probably related to the different mechanisms of action. Unlike bevacizumab, sunitinib induces a systemic VEGF release that may be partly tumor-derived (22, 23) .
Our finding that therapeutic bevacizumab/IFNa reduced 89 Zrbevacizumab tumor delivery may be explained by competition between cold and labeled antibody. However, results of preclinical and clinical studies suggest that bevacizumab-induced vascular changes are responsible (24) (25) (26) . Two studies in mice bearing human epidermal growth factor receptor-2-expressing tumors demonstrated that VEGF-A antibody treatment reduced tumor accumulation of the human epidermal growth factor receptor-2 antibody trastuzumab and a nonspecific antibody, whereas normal-tissue distribution was not altered (24, 25) . Decreased tumor accumulation was accompanied by reduced tumor vascular density and blood flow and increased pericyte coverage of tumor vessels. Furthermore, in non-small cell lung cancer patients, tumor delivery of docetaxel diminished after 1 therapeutic bevacizumab dose, which was paralleled by reduced tumor perfusion (26). Zr-bevacizumab PET scans of patient with RCC metastases in pancreas, liver, and thyroid, with associated jugular and portal vein thrombosis at baseline (left) and 2 (middle) and 6 wk (right) after start of bevacizumab/IFNα. Tumor uptake decreased whereas normal-organ uptake was stable over time. (B) Serial 89 Zr-bevacizumab PET scans of patient with RCC metastases in lungs, mediastinal lymph nodes, bone, and brain at baseline (left) and 2 (middle) and 6 wk (right) after start of sunitinib-that is, after 2 sunitinib-free weeks. Tumor 89 Zr-bevacizumab uptake decreased during treatment in lung and brain metastases but increased in normal liver and bone metastases, with reverse pattern after 2 drug-free weeks. The small decrease that we observed in mean tumor 89 Zrbevacizumab uptake after 2 wk of sunitinib and the rebound exceeding baseline after 2 wk off treatment correspond with our preclinical findings (27) . Preclinical studies showed increased invasiveness and metastasis after a short sunitinib course (4, 5) . Moreover, a profound expansion of proliferating endothelial cells was demonstrated in primary RCCs after neoadjuvant sunitinib (28), which was not observed after bevacizumab, despite similar histologic features suggestive of vascular normalization (28) . These findings support our observation of different tumor biology after sunitinib and bevacizumab/IFNa. Interestingly, the increased uptake in renal tumors during sunitinib treatment differs from results of 111 Inbevacizumab SPECT in 7 RCC patients treated with the tyrosine kinase inhibitor sorafenib for 4 wk (29) . Reduced tumor 111 Inbevacizumab uptake correlated with areas of necrosis (29) . The increase in 89 Zr-bevacizumab accumulation in the normal liver, spleen, and kidneys during sunitinib treatment is probably due to sunitinib-induced release of VEGF-A by normal cells. This corresponds with the observation of elevated VEGF protein in the liver, spleen, and kidney tissue of sunitinib-treated mice (5) .
Baseline tumor 89 Zr-bevacizumab uptake in our study was higher than in patients with early breast cancer and in patients with metastatic neuroendocrine tumors (13, 14) . This observation probably reflects the unique pathobiology of Von Hippel-Lindau gene inactivation in RCC, resulting in high VEGF-A production by tumor cells.
We had only 1 patient with progressive disease at 3 mo, and therefore no conclusions can be drawn about the ability of 89 Zrbevacizumab PET to identify primary resistant patients. Patients with intense 89 Zr-bevacizumab tumor accumulation at baseline had a longer TTP. This exploratory analysis should be interpreted with caution but may indicate that those tumors are more VEGFdriven and -dependent and therefore can be effectively controlled with antiangiogenic treatment.
The absence of a correlation between SUV max parameters and plasma VEGF-A might be due to a different composition of circulating and microenvironmental VEGF-A isoforms.
CONCLUSION
We demonstrated heterogeneous 89 Zr-bevacizumab tumor uptake in mRCC patients. Bevacizumab/IFNa strongly decreases 89 Zr-bevacizumab tumor uptake whereas sunitinib results in modest reduction with an overshoot after 2 drug-free weeks. High baseline tumor SUV max appears to be associated with longer TTP. Further studies are required to determine whether baseline 89 Zr-bevacizumab tumor uptake can be used to predict benefit from antiangiogenic treatment. To differentiate between prognostic and predictive value, a randomized study is required.
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